Keywords: gilead, ambrisentan, improves, 6mwd, ph, patients, drugmaker

Gilead's ambrisentan improves 6MWD in PH patients

Article | 20 May 2009

Print This

US drugmaker Gilead Sciences reported data from ARIES-3, an open-label, single-arm, Phase III study evaluating the efficacy and safety of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in